The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
In this article
Metsera
on Tuesday said Novo Nordisk
’s new bid for the obesity biotech is “superior” to a revised offer from Pfizer
, escalating a heated tussle over the startup between the two pharmaceutical giants.
Guerra de opa en el adelgazamiento: Novo Nordisk supera a Pfizer con su oferta por Metsera
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Pfizer vince la guerra con Novo Nordisk e acquisisce Metsera, startup di farmaci dimagranti
Novo Nordisk rilancia l’offerta su Metsera a 10 miliardi di dollari
Más tensión en Novo Nordisk: rebaja previsiones en plena guerra con Pfizer por la ‘start-up’ de moda en el adelgazamiento
The Multi-Billion-Dollar Battle For Metsera
Pfizer fa causa a Novo Nordisk sull’acquisizione di Metsera. “Controfferta viola accordi”
US regulator warns Novo Nordisk’s Metsera offer ‘may violate’ antitrust law
Pfizer lleva a los tribunales la guerra de opa con Novo Nordisk por la ‘start-up’ de moda en el adelgazamiento
Novo Nordisk wants to keep its crown leading the weight-loss drugs pack. Despite outlook downgrades and lawsuits, its CFO has a plan | Fortune
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera, after Pfizer last week made…
Pfizer said Friday it filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations.
Metsera has no products on the market, but it is developing oral and injectable treatments.
El grupo danés presenta una oferta de 6.500 millones de dólares, por encima del importe ya acordado por su rival estadounidense.…
